The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
ELISAs for urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) have shown that tumor levels of these molecules are prognostic parameters in breast cancer as well as other types of cancer. These ELISAs measure the total amount of the given component, including preforms, active, inactive, and complex-bound forms. However, the amount of the active forms of a component may more closely reflect the ongoing level of proteolytic activity and thereby be particularly related to prognosis. Since the inactive complex between uPA and PAI-1 can only be formed the active forms of the individual components, we have developed a sensitive and specific uPA:PAI-1 complex ELISA consisting of a sandwich format with two monoclonal antibodies (MAbs) against PAI-1 as capture antibodies and three biotinylated MAbs against uPA as detector antibodies. The data were collected as kinetic measurements of bound alkaline phosphatase activity. A standard of uPA:PAI-1 complex could be specifically measured in the assay with a detection limit of 8 pg/ml and a linear relationship between signal and complex concentration up to 4 ng/ml. Neither free uPA nor free PAI-1 were detected by this assay and the addition to the internal standard of free PAI-1 in amounts up to 20 ng/ml or uPA did not reduce the detection of complex by the assay. This ELISA was applied to extracts from 20 individual breast cancers. Each tumor was extracted in two different buffers and the median concentration of uPA:PAI-1 complex in the optimal extraction buffer was 0.8 ng/mg protein, range 0.4-2.8 ng/mg protein. Extraction of the tumor tissue at a low pH prevented de novo formation of complex from free uPA and PAI-1 in the tissue without destabilizing preformed uPA:PAI-1 complex. During incubation of the assay plate at neutral pH further uPA:PAI-1 complex formation from free components in the extracts was blocked by p-nitrophenyl guanidinobenzoate (NPGB). Thus, the present assay selectively quantifies preformed complex in tumor extracts and will enable us, for the first time, to evaluate the potential prognostic value of the uPA:PAI-1 complex in cancer.
Pedersen
A N
AN
Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
Høyer-Hansen
G
G
Brünner
N
N
Clark
G M
GM
Larsen
B
B
Poulsen
H S
HS
Danø
K
K
Stephens
R W
RW
D000818:Animals; D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000737:chemistry / Q000201:enzymology*; D002021:Buffers; D004797:Enzyme-Linked Immunosorbent Assay / Q000592:standards; D006801:Humans; D051379:Mice; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology; D012680:Sensitivity and Specificity; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology
D000911:Antibodies, Monoclonal; D002021:Buffers; D009097:Multienzyme Complexes; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator